Compare Palantir Technologies Inc (PLTR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Sanofi SA — how do they compare? Palantir Technologies Inc trades at $169.71 (market cap $409.24B), while Sanofi SA trades at $43.14 (market cap $104.06B). The key difference: Palantir Technologies Inc is far larger — about 3.9× Sanofi SA's market cap, and Sanofi SA pays a 5.61% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | SNY | |
|---|---|---|
Market Cap | $409.24B | $104.06B |
Sector | Technology | Health |
52-Week High | $207.18 | $52.34 |
52-Week Low | $107.27 | $41.33 |
Enterprise Value | $400.04B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $170.30, down 2.31% on the day, with technical indicators showing neutral signals amid strong fundamental performance. The company reported exceptional Q2 2026 results with EPS of $0.41 beating expectations by 19%, while revenue growth accelerated to 93% year-over-year. Recent news highlights the strategic Nebius partnership for sovereign AI infrastructure, positioning Palantir to address growing enterprise demand for private AI deployment solutions.
While valuation metrics remain elevated with P/E of 145.6 and P/S of 71.1, the company's 49% net margin and 38.4% ROE demonstrate strong profitability. The consensus price target of $211.38 suggests 24% upside potential, though competitive pressures and high expectations create execution risks. Investors face the tension between premium valuation and exceptional growth trajectory.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
